Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro.
暂无分享,去创建一个
Elisabeth Kjellén | Tomas Ohlsson | Lars Ekblad | Arne Brun | A. Brun | T. Ohlsson | E. Brun | Eva Brun | Eva Henriksson | E. Kjellén | Maria Bjurberg | M. Bjurberg | L. Ekblad | Eva Henriksson
[1] M. Schwaiger,et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Grigsby,et al. 18-F-fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer. , 2008, International journal of radiation oncology, biology, physics.
[3] E. Croteau,et al. A Small Animal Positron Emission Tomography Study of the Effect of Chemotherapy and Hormonal Therapy on the Uptake of 2-Deoxy-2-[F-18]fluoro-d-glucose in Murine Models of Breast Cancer , 2007, Molecular Imaging and Biology.
[4] S. Ben-Haim,et al. 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response* , 2008, Journal of Nuclear Medicine.
[5] T Ido,et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] O. Prante,et al. Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[7] Johan Wennerberg,et al. 2-Deoxy-2-[18F] fluoro-D-glucose uptake and correlation to intratumoral heterogeneity. , 2007, Anticancer research.
[8] 18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response , 2006, British Journal of Cancer.
[9] J. Nährig,et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Alavi,et al. Defining co-related parameters between ‘metabolic’ flare and ‘clinical’, ‘biochemical’, and ‘osteoblastic’ flare and establishing guidelines for assessing response to treatment in cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[11] Patrick Dupont,et al. [18F]FDG PET monitoring of tumour response to chemotherapy: does [18F]FDG uptake correlate with the viable tumour cell fraction? , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[12] J. Wennerberg. Changes in growth pattern of human squamous‐cell carcinomas of the head and neck during serial passages in nude mice , 1984, International journal of cancer.
[13] W. Oyen,et al. Predictive and prognostic value of FDG‐PET in nonsmall‐cell lung cancer , 2007, Cancer.
[14] Wolfgang A. Weber,et al. Monitoring chemotherapy and radiotherapy of solid tumors , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[15] Å. Borg,et al. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck , 2006, Acta oncologica.
[16] Wolfgang A Weber,et al. Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] M. Welch,et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Vaupel,et al. Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.
[19] T. Hickish,et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Martin Hutchings,et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.